Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 41

1.

Anti-hepatitis B virus activity and metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine.

Zhu YL, Dutschman DE, Liu SH, Bridges EG, Cheng YC.

Antimicrob Agents Chemother. 1998 Jul;42(7):1805-10.

3.

Inhibition of replication of hepatitis B virus by cytallene in vitro.

Zhu YL, Pai SB, Liu SH, Grove KL, Jones BC, Simons C, Zemlicka J, Cheng YC.

Antimicrob Agents Chemother. 1997 Aug;41(8):1755-60.

4.

Effect of stereoisomerism on the cellular pharmacology of beta-enantiomers of cytidine analogs in Hep-G2 cells.

Martin LT, Faraj A, Schinazi RF, Gosselin G, Mathe C, Imbach JL, Sommadossi JP.

Biochem Pharmacol. 1997 Jan 10;53(1):75-87.

PMID:
8960066
5.

A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team.

Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, Henry WK, Lederman MM, Phair JP, Niu M, Hirsch MS, Merigan TC.

N Engl J Med. 1996 Oct 10;335(15):1081-90.

7.

Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.

Staszewski S, Loveday C, Picazo JJ, Dellarnonica P, Skinhøj P, Johnson MA, Danner SA, Harrigan PR, Hill AM, Verity L, McDade H.

JAMA. 1996 Jul 10;276(2):111-7.

PMID:
8656502
9.

Favorable interaction of beta-L(-) nucleoside analogues with clinically approved anti-HIV nucleoside analogues for the treatment of human immunodeficiency virus.

Bridges EG, Dutschman GE, Gullen EA, Cheng YC.

Biochem Pharmacol. 1996 Mar 22;51(6):731-6. Erratum in: Biochem Pharmacol 1996 May 17;51(10):1415.

PMID:
8602867
10.

Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.

Collier AC, Coombs RW, Schoenfeld DA, Bassett RL, Timpone J, Baruch A, Jones M, Facey K, Whitacre C, McAuliffe VJ, Friedman HM, Merigan TC, Reichman RC, Hooper C, Corey L.

N Engl J Med. 1996 Apr 18;334(16):1011-7.

11.

Rapid screening of antiretroviral combinations.

St Clair M, Pennington KN, Rooney J, Barry DW.

J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10 Suppl 1:S24-7. Review.

PMID:
8595504
12.
13.

L-beta-(2S,4S)- and L-alpha-(2S,4R)-dioxolanyl nucleosides as potential anti-HIV agents: asymmetric synthesis and structure-activity relationships.

Kim HO, Schinazi RF, Shanmuganathan K, Jeong LS, Beach JW, Nampalli S, Cannon DL, Chu CK.

J Med Chem. 1993 Mar 5;36(5):519-28.

PMID:
8496934
14.

Nucleoside analogs: similarities and differences.

Sommadossi JP.

Clin Infect Dis. 1993 Feb;16 Suppl 1:S7-15. Review.

PMID:
8425021
17.
18.

Anti-human immunodeficiency virus activities of the beta-L enantiomer of 2',3'-dideoxycytidine and its 5-fluoro derivative in vitro.

Gosselin G, Schinazi RF, Sommadossi JP, Mathé C, Bergogne MC, Aubertin AM, Kirn A, Imbach JL.

Antimicrob Agents Chemother. 1994 Jun;38(6):1292-7.

19.

Metabolism of carbovir, a potent inhibitor of human immunodeficiency virus type 1, and its effects on cellular metabolism.

Parker WB, Shaddix SC, Bowdon BJ, Rose LM, Vince R, Shannon WM, Bennett LL Jr.

Antimicrob Agents Chemother. 1993 May;37(5):1004-9.

20.

Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides.

Schinazi RF, Lloyd RM Jr, Nguyen MH, Cannon DL, McMillan A, Ilksoy N, Chu CK, Liotta DC, Bazmi HZ, Mellors JW.

Antimicrob Agents Chemother. 1993 Apr;37(4):875-81.

Supplemental Content

Support Center